Hepatitis B Topics HBV Disease Progression
EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 27 April 2012 00:00
- Written by Liz Highleyman
The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
Statins May Reduce Liver Cancer Risk among People with Hepatitis B
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 10 February 2012 00:00
- Written by Liz Highleyman
Statins, a class of drugs used to manage elevated blood cholesterol, may also play a role in fighting hepatocellular carcinoma (HCC) -- a form of primary liver cancer -- among people with chronic hepatitis B, according to a report in the January 23, 2012, advance online edition of the Journal of Clinical Oncology.
MicroRNA Blood Test May Help Diagnose Early Liver Cancer in People with Hepatitis B
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 03 January 2012 00:00
- Written by Liz Highleyman
A set of 7 microRNAs in blood plasma accurately diagnosed hepatocellular carcinoma (HCC) and could distinguish between liver cancer and cirrhosis among people with chronic hepatitis B, according to study findings reported in the November 21, 2011, advance online edition of the Journal of Clinical Oncology.
High HBV Viral Load Linked to Greater Risk of Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 17 January 2012 00:00
- Written by Liz Highleyman
Having a high blood level of hepatitis B virus (HBV) DNA increases the likelihood of developing hepatocellular carcinoma (HCC), a form of primary liver cancer, according to a study described in the January 13, 2012, Journal of Virology.
AASLD 2011: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
Doubling the usual dose of entecavir (Baraclude) did not increase its effectiveness for treating chronic hepatitis B, according to a study presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) this month in San Francisco.
Hepatitis B and C Are Major Causes of Liver Cancer in U.S.
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 10 January 2012 00:00
- Written by Press Release
Chronic hepatitis C infection has replaced alcohol-related cirrhosis as a major cause of hepatocellular carcinoma (HCC, a form of primary liver cancer) in the U.S., according to a study by researchers at the Mayo Clinic in Rochester, MN. A related analysis found that among immigrants from Somalia, hepatitis B and C were both significant causes of liver cancer.
AASLD 2011: Good Response to Entecavir Reduces Risk of Hepatitis B Liver Disease Progression
- Details
- Category: HBV Treatment
- Published on Tuesday, 22 November 2011 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who achieve HBV DNA viral load suppression on entecavir (Baraclude) have a lower risk of liver failure, hepatocellular carcinoma, and death than non-responders, according to study findings presented this month at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
More Articles...
- AASLD 2011: Engineered Poxvirus Shows Promise for Treating Advanced Liver Cancer
- Changes Proposed for Allocation of Donated Livers
- Hepatitis Delta Found in 15% of HIV/HBV Coinfected People, Increases Risk of Death
- High HBV Viral Load Predicts Liver Fibrosis and Cancer
- Deferoxamine Shows Promise for Liver Cancer in People with Advanced Disease
Web Design and Development by